Focus No. 90

Mind Soak

FOCUS NO. 90

Cognitive Clarity Complex

ADHD Support Without Stimulants

This formula does not replicate stimulant medications. It makes no claim to produce the immediate, high-magnitude dopamine increases that prescription amphetamines and methylphenidate provide — and it would be clinically irresponsible to suggest otherwise.

What it addresses is the underlying neurochemical and nutritional terrain that makes ADHD symptoms worse: dopamine synthesis insufficiency, impaired prefrontal cortex phospholipid signaling, omega-3 deficiency, methylation pathway dysfunction, and acetylcholine depletion. These are measurable, correctable deficits that compound executive function impairment independently of medication status.

Think of this formula as optimizing the substrate — giving the brain the structural integrity, precursor availability, and cofactor support it needs to sustain attention, reduce mental fatigue, and improve working memory, whether medication is part of the treatment plan or not.

Safe to take alongside stimulant medications (amphetamine salts, methylphenidate) and non-stimulants (atomoxetine, guanfacine, clonidine). These ingredients work through distinct mechanisms and do not potentiate stimulant cardiovascular effects. Always inform your prescribing provider about supplements you are taking.

Formula Ingredients

Omega-3 EPA (AvailOm®)

714 mg
31% EPA · 15% DHA · Algal-Sourced · Re-Esterified Triglyceride Form

What it does

ADHD is consistently associated with lower omega-3 status — particularly EPA and DHA — across multiple independent research cohorts. Omega-3 fatty acids are structural components of neuronal cell membranes; inadequate levels directly impair the fluidity and receptor density of dopaminergic and noradrenergic synapses in the prefrontal cortex, the region most responsible for executive function, impulse control, and working memory. EPA specifically modulates neuroinflammation, reduces pro-inflammatory cytokine activity that impairs dopamine transmission, and supports phosphatidylserine synthesis in neural tissue. Multiple randomized controlled trials have demonstrated measurable improvements in ADHD symptom severity, inattention, and hyperactivity/impulsivity scores with EPA-dominant omega-3 supplementation — both as monotherapy and as augmentation to stimulant medication.


Why this dose

AvailOm® uses a re-esterified triglyceride structure that increases bioavailability approximately 70% over standard ethyl ester fish oil, meaning 714mg of this form delivers plasma EPA and DHA exposures equivalent to meaningfully higher doses of conventional supplements. The EPA:DHA ratio of approximately 2:1 is consistent with the ratio used in positive ADHD intervention studies, where EPA-dominant formulations consistently outperform balanced or DHA-dominant products for attention and behavioral outcomes. The algal source eliminates mercury and PCB exposure concerns while providing the identical fatty acid profile. At this dose taken consistently, meaningful correction of omega-3 insufficiency is typically achieved within 6–8 weeks.

L-Tyrosine

500 mg

What it does

L-tyrosine is the direct dietary precursor to dopamine and norepinephrine — the two catecholamines most implicated in ADHD pathophysiology. The biosynthetic pathway is: L-tyrosine → L-DOPA (via tyrosine hydroxylase, rate-limited by B6 and folate) → dopamine (via aromatic amino acid decarboxylase) → norepinephrine (via dopamine-beta-hydroxylase). By providing the precursor substrate in meaningful quantity, this ingredient supports endogenous catecholamine production independent of stimulant mechanisms. L-tyrosine is particularly effective under conditions of cognitive demand and stress, where catecholamine depletion is most pronounced — which describes the daily functional experience of individuals with ADHD during demanding tasks. Unlike stimulant medications, it does not force catecholamine release but supports synthesis capacity.


Why this dose

Published cognitive enhancement studies with L-tyrosine have used 100mg/kg body weight (approximately 7,000–10,000mg for an average adult) in acute stress paradigms, and 500–2,000mg/day in chronic supplementation protocols. 500mg is a conservative foundational dose — positioned to provide consistent precursor availability without the overstimulation risk that can occur at higher doses in sensitive individuals. It is most effective when the downstream cofactors are simultaneously present, which is the design logic of this formula: B6 (P5P) ensures the tyrosine hydroxylase and decarboxylase reactions proceed efficiently, and methylfolate with B12 supports the methylation steps downstream in catecholamine metabolism. For individuals who do not respond at 500mg, the dose can be increased to 1,000mg independently.

L-Theanine

250 mg
What it does

ADHD brains are not simply under-stimulated — they are frequently dysregulated, oscillating between mental hyperactivity, distraction, and cognitive overload. L-theanine addresses this dysregulation by increasing alpha brain wave activity, the oscillatory state associated with calm, present-moment attention. It reduces glutamate-driven excitability in the default mode network — the cognitive system most responsible for mind-wandering and task-irrelevant internal thought, which is hyperactive in ADHD. Simultaneously, it elevates GABA, dopamine, and serotonin, creating the neurochemical conditions for sustained, settled attention rather than effortful, fragile focus. When combined with the dopaminergic support from L-tyrosine and citicoline, L-theanine contributes a qualitative shift: focus that is relaxed and enduring rather than tense and brittle.


Why this dose

200mg is the well-validated threshold for measurable alpha wave enhancement and anxiolytic effect. This formula uses 250mg to account for the higher glutamate excitability that characterizes ADHD neurobiology, providing slightly more robust default mode network suppression than the standard anxiolytic dose. It does not cause sedation at this level and does not impair the alerting and motivational effects of the dopaminergic ingredients. In the context of stimulant co-administration, L-theanine at 250mg can attenuate the jitteriness, cardiovascular arousal, and rebound anxiety that some individuals experience without meaningfully blunting therapeutic focus effects.

Citicoline (CDP-Choline)

500 mg

What it does

Citicoline is among the most rigorously studied cognitive ingredients in the literature, with mechanisms directly relevant to ADHD neurobiology. It serves as a precursor to both phosphatidylcholine — the primary structural phospholipid of neuronal cell membranes — and acetylcholine, the neurotransmitter most responsible for attention, learning consolidation, and working memory. In ADHD, prefrontal cortex cell membrane integrity and acetylcholine signaling are both compromised relative to neurotypical controls. Citicoline also directly increases dopamine receptor density and enhances dopamine transporter expression, improving both dopamine release efficiency and reuptake regulation. It supports cerebral energy metabolism via cytidine's conversion to uridine, a substrate for brain ATP production. Clinical studies have demonstrated improvements in attention, processing speed, and executive function in both ADHD populations and healthy adults under cognitive demand.


Why this dose

Clinical studies on citicoline have used 250–1,000mg/day, with the most consistent cognitive outcomes observed at 500mg. At this dose, citicoline reliably elevates brain phosphatidylcholine levels, increases acetylcholine synthesis, and produces measurable improvements in attention and memory on standardized assessments within 4–6 weeks of daily use. The 500mg dose is the minimum required for meaningful dopamine receptor density effects, as lower doses (250mg) produce phospholipid precursor benefits without the full dopaminergic receptor upregulation that is most relevant to ADHD. It is well tolerated at this dose; headache risk is associated with doses above 1,000mg and is not a concern at 500mg.

Folate (L-5-MTHF)

680 mcg DFE
As L-5-Methyltetrahydrofolate · Bypasses MTHFR Variants

What it does

L-methylfolate is a required cofactor for the synthesis of all three major monoamine neurotransmitters — dopamine, norepinephrine, and serotonin — through its role in generating tetrahydrobiopterin (BH4), the essential cofactor for tyrosine hydroxylase and tryptophan hydroxylase. Without adequate methylfolate, these rate-limiting enzymes cannot function at full capacity regardless of precursor availability. MTHFR gene variants — present in 40–60% of the population — impair conversion of dietary folic acid to the active methylfolate form, creating a functional folate insufficiency that is invisible on standard folic acid repletion. Research specifically linking MTHFR variants with ADHD severity has strengthened the rationale for active folate supplementation in this population. L-methylfolate bypasses the MTHFR conversion step entirely and is immediately available for BH4 synthesis.


Why this dose

680mcg DFE of L-5-MTHF represents a meaningful therapeutic dose above the standard 400mcg RDA, reflecting the higher threshold needed to saturate BH4 synthesis pathways and fully support catecholamine production in the context of this formula's L-tyrosine load. It is lower than the 1,020mcg used in the Mood formula because the focus here is specifically on dopamine and norepinephrine pathway cofactor support rather than full methylation cycle repletion for mood. This dose works in biochemical synergy with the B6 (P5P) and B12 in this formula: all three are required for complete, efficient catecholamine synthesis — none is sufficient in isolation.

Vitamin B6

5 mg
As Pyridoxal-5'-Phosphate (P5P) · Active Coenzyme Form

What it does

Pyridoxal-5'-phosphate is the biologically active coenzyme form of vitamin B6 and is the required cofactor for aromatic L-amino acid decarboxylase (AADC) — the enzyme that converts L-DOPA to dopamine and 5-HTP to serotonin. Without adequate P5P, the L-tyrosine in this formula cannot complete its conversion to dopamine regardless of tyrosine hydroxylase activity. P5P is also involved in GABA synthesis (as cofactor for glutamate decarboxylase) and in over 100 enzymatic reactions in the brain. The active P5P form is used here because a meaningful subset of individuals — particularly those with B6 processing polymorphisms or pyridoxine kinase insufficiency — cannot efficiently convert standard pyridoxine (B6) to its active coenzyme form. Providing P5P directly eliminates this conversion bottleneck.


Why this dose

5mg of P5P is a targeted cofactor dose — sufficient to ensure AADC activity is not rate-limited by B6 availability, without approaching the upper limit where peripheral neuropathy risk begins to emerge (typically associated with sustained doses above 100mg/day of pyridoxine, with a more conservative threshold for P5P). The RDA for B6 is 1.3–1.7mg/day; 5mg exceeds this to account for the elevated cofactor demand created by the L-tyrosine load in this formula. In the context of converting 500mg of L-tyrosine to catecholamines, baseline dietary B6 intake alone is unlikely to provide sufficient AADC cofactor saturation. This dose is safe for long-term daily use and does not require cycling.

Vitamin B12

400 mcg
As Methylcobalamin · Active Neurological Form

What it does

Methylcobalamin completes the methylation triad alongside L-methylfolate and P5P in this formula, supporting the SAMe-dependent methylation reactions required for catecholamine synthesis, dopamine receptor maintenance, and myelin integrity. B12 deficiency produces cognitive symptoms directly overlapping with ADHD presentation: poor concentration, processing speed reduction, working memory impairment, and mental fatigue. In the context of ADHD management, B12 also supports the integrity of the myelin sheaths surrounding prefrontal cortex projection neurons — impaired myelination reduces conduction velocity in frontal-striatal circuits, the neural pathway most implicated in executive function deficits. Methylcobalamin is the neurologically active form; cyanocobalamin requires hepatic conversion and delivers less bioavailable B12 to the central nervous system per unit dose.


Why this dose

400mcg of methylcobalamin provides full methylation pathway cofactor support without exceeding what is necessary at this formula's design level. It is lower than the 1,000mcg used in the Mood formula because the primary application here is cofactor completeness for catecholamine synthesis rather than aggressive deficiency repletion for mood-spectrum conditions. At 400mcg, passive absorption via diffusion delivers adequate methylcobalamin to the CNS in individuals with intact intrinsic factor function. Individuals with suspected B12 malabsorption (long-term metformin or PPI use, history of gastric surgery, age over 60) may benefit from a higher standalone B12 dose and should discuss this with their provider. At 400mcg, no adverse effects have been documented in the literature at any level of intake.

How These Ingredients Work Together

Seven Ingredients. One Integrated Dopamine Architecture.

🔗

Dopamine Production Chain

L-tyrosine provides the raw precursor. P5P activates the decarboxylase enzyme that converts it. L-methylfolate and B12 generate the BH4 cofactor required for tyrosine hydroxylase. Every enzymatic step in dopamine synthesis is supported — not just the starting material.

🧠

Prefrontal Cortex Structure

Citicoline rebuilds phosphatidylcholine in neuronal membranes and increases dopamine receptor density. EPA-dominant omega-3s maintain membrane fluidity and synaptic receptor function. Together they address the structural deficits in prefrontal dopaminergic signaling that standard precursor support alone cannot correct.

⚡

Sustained vs. Brittle Focus

L-theanine suppresses default mode network hyperactivity and reduces glutamate excitability, converting effortful, easily disrupted attention into settled, enduring focus. Without this component, dopaminergic precursor support can produce drive without direction — energy without sustained executive control.

🔄

Addressing Root Deficits

ADHD brains consistently show lower omega-3 status, impaired methylation, and B-vitamin insufficiency relative to neurotypical controls. This formula does not add stimulation on top of deficiency — it corrects the deficits that compound ADHD symptoms and undermine medication effectiveness.

How to Use This Formula

Dosing & Timing

  • Timing Take in the morning with a protein-containing meal. L-tyrosine competes with other large neutral amino acids for transport — a light protein meal (rather than a carbohydrate-heavy breakfast) optimizes absorption. Omega-3s and fat-soluble nutrients require dietary fat for absorption.
  • With Meds Safe alongside stimulant medications (Adderall, Vyvanse, Ritalin, Concerta) and non-stimulants (Strattera, Intuniv, Kapvay). Mechanisms are additive through distinct pathways. L-theanine may attenuate stimulant-associated jitteriness and rebound without reducing therapeutic focus benefit. Inform your prescriber.
  • Consistency Omega-3s and citicoline's structural effects accumulate over 4–8 weeks of daily use. L-tyrosine and L-theanine produce noticeable acute effects within the first dose window. B-vitamin cofactor normalization typically becomes meaningful by week 2–3. Do not assess efficacy until 6 weeks of consistent daily use.
  • Adjusting If stimulant medication is already producing adequate focus but with excessive side effects, consider this formula as standalone support on non-medication days or as a lower-stimulant-dose adjunct. If tolerance to stimulants has developed over time, the dopamine precursor and receptor density support in this formula may partially address tolerance-related efficacy decline.
  • Tyrosine Note L-tyrosine is most effective when taken during or shortly before periods of cognitive demand. Individuals with hyperthyroidism or those taking thyroid medications should consult their prescriber before use, as tyrosine is also a precursor to thyroid hormones.
  • Diet Adequate dietary protein is essential — it provides the tryptophan and tyrosine the formula's enzymes are designed to process. High-sugar, processed-food diets drive neuroinflammation that directly opposes EPA's mechanism. Consistent meal timing supports more predictable catecholamine synthesis throughout the day.

What You'll Notice

Expected Response Timeline

Day 1 – 3

L-tyrosine and citicoline produce the most immediate effects — improved ability to initiate tasks, reduced mental friction at the start of work sessions, and a cleaner quality of focus without the cardiovascular arousal of stimulants. L-theanine reduces background cognitive noise within the first dose window. These effects are real but not maximal — the structural and cofactor mechanisms have not yet accumulated.

Week 1 – 2

B-vitamin methylation support normalizes. The conversion of L-tyrosine to dopamine becomes more efficient as P5P and methylfolate reach adequate tissue levels. Working memory begins to improve — specifically, the ability to hold multiple pieces of information simultaneously without losing track. Transition between tasks becomes less cognitively costly. Individuals on stimulant medication may notice a smoother, more consistent effect profile.

Week 3 – 4

Citicoline-driven increases in acetylcholine and phosphatidylcholine become meaningful. Attention quality shifts from effortful and fragile to more automatic and durable. Reading comprehension and the ability to follow multi-step processes improve noticeably. The default mode network disruption that characterizes ADHD — intrusive, task-irrelevant thoughts during focused work — decreases in frequency and intensity.

Week 6 – 8

Full formula benefit is established as EPA-driven omega-3 repletion reaches steady state. Prefrontal membrane integrity is meaningfully improved, supporting the dopamine receptor density and synaptic efficiency gains initiated by citicoline. Executive functions — planning, prioritizing, following through on multi-step tasks, managing time — become measurably more accessible. The improvement is not a stimulant-like override of ADHD; it is a reduction in the neurochemical friction that makes executive function so effortful.

Clinical Scope

When This Formula Is Not Sufficient

  • Combined-type ADHD with significant hyperactivity and impulsivity causing safety or occupational impairment
  • Moderate-to-severe ADHD where functioning is substantially compromised across multiple domains — academic, occupational, relational
  • ADHD presenting with significant emotional dysregulation, rejection sensitivity, or mood instability that requires pharmacological management
  • You have trialed stimulant and non-stimulant medications without adequate response — this pattern warrants comprehensive psychiatric evaluation, not further supplement optimization
  • You need rapid, high-magnitude improvement — this formula builds gradually and does not produce the acute, dramatic cognitive shift that stimulant medications provide from day one
  • Comorbid conditions (bipolar disorder, psychosis, severe anxiety) where ADHD pharmacotherapy requires careful prescriber management

This formula is appropriate for mild ADHD, inattentive presentation, subclinical executive function difficulties, and as adjunct nutritional support for individuals on ADHD medication. It is not a substitute for stimulant or non-stimulant medication in moderate-to-severe presentations.

Summary

The Bottom Line

This formula does not try to be Adderall. That would be both impossible and misleading.

What it does is address the nutritional and neurochemical deficits that compound ADHD symptoms independent of medication status: omega-3 insufficiency impairing prefrontal membrane function, impaired methylation limiting catecholamine synthesis, B-vitamin cofactor depletion bottlenecking enzymatic conversion, and acetylcholine insufficiency undermining attention consolidation.

Correcting these deficits does not cure ADHD. It removes the additional neurochemical burden that makes an already-challenging condition harder to manage — and in some cases, that correction alone is clinically meaningful.

Formulated by a psychiatric nurse practitioner who treats ADHD daily and understands what the research actually demonstrates about non-pharmacological support.